文献速递儿科与产科急症重症综合管理与镇静镇痛

儿童多系统炎症综合征的治疗

Treatment of Multisystem Inflammatory Syndrome in Children.
PubMed 文献 · N Engl J Med · 2021-06-16
一句话结论国际观察性队列显示,MIS-C 初始单用 IVIG、IVIG 联合糖皮质激素或单用糖皮质激素,在复合不良结局与病情严重度改善上未见差异。

该国际观察性队列研究分析了2020年6月至2021年2月来自32个国家的614例疑似MIS-C患儿数据(其中490例符合世界卫生组织MIS-C标准),采用逆概率加权和广义线性模型,以单用静脉注射免疫球蛋白(IVIG)为参照,比较IVIG联合糖皮质激素与单用糖皮质激素。主要复合终点(第2天及以后需正性肌力支持或机械通气或死亡)在IVIG联合糖皮质激素组为56例(校正OR 0.77,95%CI 0.33–1.82),单用糖皮质激素组为17例(校正OR 0.54,95%CI 0.22–1.33);第2天病情严重度改善的校正OR分别为0.90和0.93,三组病情改善时间相似。作者认为未见三种初始治疗方案在MIS-C恢复上存在差异,但随着数据积累可能出现显著差异。

要点

  • 614例疑似MIS-C患儿中490例符合世界卫生组织MIS-C标准;246例单用IVIG、208例IVIG联合糖皮质激素、99例单用糖皮质激素。
  • 主要复合终点(第2天及以后正性肌力支持或机械通气或死亡):IVIG联合糖皮质激素组56例,校正OR 0.77(95%CI 0.33–1.82);单用糖皮质激素组17例,校正OR 0.54(95%CI 0.22–1.33),均以单用IVIG为参照。
  • 第2天病情严重度改善的校正OR:IVIG联合糖皮质激素0.90、单用糖皮质激素0.93(均以单用IVIG为参照)。
  • 三组病情严重度改善时间相似。
  • 作者结论:未见单用IVIG、IVIG联合糖皮质激素或单用糖皮质激素初始治疗后MIS-C恢复存在差异,但随着更多数据积累可能出现显著差异。

适用人群与场景

  • 疑似MIS-C患儿,临床与结局数据由医生上传至网络数据库,来自32个国家,时间2020年6月至2021年2月;其中490例符合世界卫生组织MIS-C标准。

诊断标准与关键阈值

  • 世界卫生组织MIS-C标准(490例符合)。

处置流程与药物剂量

  • 初始治疗:246例单用IVIG,208例IVIG联合糖皮质激素,99例单用糖皮质激素;22例接受其他联合治疗(包括生物制剂),39例未接受免疫调节治疗。

研究设计与关键结果

  • 国际观察性队列研究,614例疑似MIS-C患儿来自32个国家,2020年6月至2021年2月;采用逆概率加权和广义线性模型,以单用IVIG为参照比较IVIG联合糖皮质激素与单用糖皮质激素。
  • 主要复合终点(第2天及以后正性肌力支持或机械通气或死亡):IVIG联合糖皮质激素组56例,校正OR 0.77(95%CI 0.33–1.82);单用糖皮质激素组17例,校正OR 0.54(95%CI 0.22–1.33)。
  • 第2天病情严重度改善的校正OR:IVIG联合糖皮质激素0.90、单用糖皮质激素0.93(均以单用IVIG为参照)。
  • 三组病情严重度改善时间相似。
  • 次要结局包括治疗升级、器官衰竭和炎症改善时间。

证据类型、等级与局限

  • 证据类型:国际观察性队列研究。
  • 局限:作者指出,随着更多数据积累,可能出现显著差异。

对床旁实践的改变

  • 作者认为,单用IVIG、IVIG联合糖皮质激素或单用糖皮质激素初始治疗后MIS-C恢复未见差异,但随着更多数据积累可能出现显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Evidence is urgently needed to support treatment decisions for children with multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2.

METHODS: We performed an international observational cohort study of clinical and outcome data regarding suspected MIS-C that had been uploaded by physicians onto a Web-based database. We used inverse-probability weighting and generalized linear models to evaluate intravenous immune globulin (IVIG) as a reference, as compared with IVIG plus glucocorticoids and glucocorticoids alone. There were two primary outcomes: the first was a composite of inotropic support or mechanical ventilation by day 2 or later or death; the second was a reduction in disease severity on an ordinal scale by day 2. Secondary outcomes included treatment escalation and the time until a reduction in organ failure and inflammation.

RESULTS: Data were available regarding the course of treatment for 614 children from 32 countries from June 2020 through February 2021; 490 met the World Health Organization criteria for MIS-C. Of the 614 children with suspected MIS-C, 246 received primary treatment with IVIG alone, 208 with IVIG plus glucocorticoids, and 99 with glucocorticoids alone; 22 children received other treatment combinations, including biologic agents, and 39 received no immunomodulatory therapy. Receipt of inotropic or ventilatory support or death occurred in 56 patients who received IVIG plus glucocorticoids (adjusted odds ratio for the comparison with IVIG alone, 0.77; 95% confidence interval [CI], 0.33 to 1.82) and in 17 patients who received glucocorticoids alone (adjusted odds ratio, 0.54; 95% CI, 0.22 to 1.33). The adjusted odds ratios for a reduction in disease severity were similar in the two groups, as compared with IVIG alone (0.90 for IVIG plus glucocorticoids and 0.93 for glucocorticoids alone). The time until a reduction in disease severity was similar in the three groups.

CONCLUSIONS: We found no evidence that recovery from MIS-C differed after primary treatment with IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone, although significant differences may emerge as more data accrue. (Funded by the European Union's Horizon 2020 Program and others; BATS ISRCTN number, ISRCTN69546370.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. McArdle AJ, Vito O, Patel H, et al. Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2021. PMID: 34133854. doi:10.1056/NEJMoa2102968

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。